血清前梯度蛋白2水平与鼻咽癌患者临床病理特征的关系  

Correlation between the level of serum anterior gradient 2 and clinical pathological characteristics of nasopharyngeal carcinoma patients

作　　者：赖世佳[1] 赵德安[1] 童梓德[1] 

机构地区：[1]厦门大学附属成功医院暨解放军第174医院耳鼻喉科,361003

出　　处：《国际肿瘤学杂志》2017年第7期496-499,共4页Journal of International Oncology

摘　　要：目的 通过检测鼻咽癌患者治疗前后血清前梯度蛋白2（AGR2）的水平,探讨其与鼻咽癌临床病理特征的关系.方法 采用酶联免疫吸附试验（ELISA）检测55例鼻咽癌患者（鼻咽癌组）治疗前后、30例鼻咽喉部炎症患者（炎症组）和20例健康志愿者（健康对照组）的血清AGR2水平,并分析治疗前后AGR2与鼻咽癌临床病理特征的关系.鼻咽癌患者均给予放疗,治疗结束后随访6个月,进行近期疗效评价.结果 治疗前鼻咽癌组、炎症组和健康对照组血清AGR2水平分别为（22.92±5.24）μg/L、（9.50±4.15）μg/L和（8.75±2.18）μg/L,3组间差异有统计学意义（F=268.400,P=0.000）,其中鼻咽癌组患者血清AGR2水平明显高于炎症组和健康对照组（t=14.241,P=0.000;t=15.254,P=0.000）.鼻咽癌组患者治疗后血清AGR2水平较治疗前明显降低[（15.15±10.33）μg/L∶（22.92±5.24）μg/L,t=12.774,P=0.000）];Ⅲ~Ⅳ期鼻咽癌患者治疗前及治疗后血清AGR2水平明显高于Ⅰ~Ⅱ期（t=5.938,P=0.000;t=0.759,P=0.032）;有淋巴结转移患者治疗前及治疗后血清AGR2水平明显高于无淋巴结转移者（t=6.879,P=0.000;t=2.700,P=0.009）;有颈动脉鞘、颅底受累者治疗前血清AGR2水平分别高于无受累者（t=8.342,P=0.000;t=8.255,P=0.009）;颅神经受累者治疗前后血清AGR2水平均明显高于无受累者（t=7.743,P=0.000;t=3.021,P=0.004）.治疗完全有效患者治疗后血清AGR2水平[（13.86±2.93）μg/L]明显低于部分有效患者[（15.85±3.24）μg/L,t=2.267,P=0.028]和无效患者[（20.65±6.59）μg/L,t=4.935,P=0.000],部分有效患者血清AGR2水平明显低于无效患者（t=3.196,P=0.004）.结论 鼻咽癌患者血清AGR2增高,在鼻咽癌发生发展过程中起到重要的作用,有望成为鼻咽癌患者临床疗效及预后判断的一个新指标.Objective To determine the levels of serum anterior gradient 2 （AGR2） before and after treatment in nasopharyngeal carcinoma （NPC） patients, and investigate the relationship of AGR2 and clinical pathological characteristics of NPC patients.Methods The serum levels of AGR2 were detected by enzyme linked immunosorbent assay （ELISA） in 55 NPC patients （NPC group） before and after treatment, 30 patients with nasopharyngeal inflammation （inflammation group） and 20 healthy controls （health control group）.The correlations between serum AGR2 before and after treatment and clinical pathological characteristics of NPC were analyzed.The NPC patients received radiotherapy and were followed up for 6 months, and the therapeutic effect was evaluated.Results The serum AGR2 levels in NPC group before treatment, inflammation group and health control group were （22.92±5.24）μg/L, （9.50±4.15）μg/L and （8.75±2.18）μg/L respectively, and the difference was statistically significant （F=268.400, P=0.000）.The level of serum AGR2 in NPC group was obviously higher than that in inflammation group （t=14.241, P=0.000） and health control group （t=15.254, P=0.000）.The level of serum AGR2 in NPC group after treatment was significantly lower than that before treatment [（15.15±10.33）μg/L vs.（22.92±5.24）μg/L, t=12.774, P=0.000].In NPC patients, serum AGR2 levels of clinical Ⅲ-Ⅳ stage group before and after treatment were higher than those of clinical Ⅰ-Ⅱ stage group （t=5.938, P=0.000;t=0.759, P=0.032）.Serum AGR2 levels of lymph node metastasis group before and after treatment were higher than those of no lymph node metastasis group （t=6.879, P=0.000;t=2.700, P=0.009）.Serum AGR2 levels of carotid sheath and skull base involvement groups before treatment were higher than those of non-involvement groups （t=8.342, P=0.000;t=8.255, P=0.009）.Serum AGR2 levels of cranial nerve involvement group before and after treatment were higher than those of non-involvement group （t=

关 键 词：鼻咽肿瘤 病理学 临床 前梯度蛋白2 

分 类 号：R739.63[医药卫生—肿瘤]